Antitumor compounds based on a natural product consensus pharmacophore

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Biology

Background:

• The spliceosome is a critical cellular machinery involved in RNA processing.
• Spliceosome inhibitors like FR901464 show promise as anti-cancer agents.
• Developing novel scaffolds is crucial for overcoming resistance and improving therapeutic profiles.

Purpose of the Study:

• To design and synthesize a potent analogue of FR901464 using a non-natural product scaffold.
• To explore a pharmacophore hypothesis linking FR901464 and pladienolide interactions.
• To evaluate the in vitro anti-cancer activity of the novel compound.

Main Methods:

• Pharmacophore modeling to guide compound design.
• Highly enantioselective synthesis of the target analogue.
• In vitro cytotoxicity assays against various human tumor cell lines.

Main Results:

• Successful design and synthesis of a novel spliceosome inhibitor analogue.
• Demonstrated potent in vitro activity against several tested tumor cell lines.
• Established a synthetic route amenable to generating diverse analogues.

Conclusions:

• The novel scaffold provides a promising platform for developing new spliceosome-targeting anti-cancer drugs.
• The compound exhibits significant anti-tumor potential warranting further investigation.
• The synthetic strategy enables rapid exploration of structure-activity relationships.